EICHORCondition: Influenza · Sponsor: Hoffmann-La Roche
The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to \< 12 years with influenza symptoms.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| The First People's Hospital of Changde | Changde, China | — |
| Peoples Hospital of Hunan Province | Changsha, China | — |
| Chengdu Women's and Children's Central Hospital | Chengdu, China | — |
| Chongqing University Jiangjin Hospital | Chongqing, China | — |
| Childern's Hospital of Chongqing Medical University | Chongqing, China | — |
| Hebei Petro China Central Hospital | Langfang, China | — |
| Liaocheng people's Hospital | Liaocheng, China | — |
| Linfen Central Hospital | Linfen, China | — |
| Liuzhou People's Hospital | Liuzhou, China | — |
| Ningbo Women and Children's Hospital | Ningbo, China | — |
| Sanmenxia Central Hospital | Sanmenxia, China | — |
| The Third People's Hospital of Hainan Province | Sanya, China | — |
+ 4 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06774859